ALIVUS

Alivus Life Sciences benefits from strong management efficiency, reflected in a return on equity (ROE) exceeding 19%, which is a key indicator of effective capital utilisation. The company’s net-debt-free status further enhances its financial stability, reducing risk and providing flexibility for future growth initiatives. Valuation metrics also support the stock’s appeal; with a price-to-book value around 4.5, it trades at a fair level relative to its historical peer group averages. Profit growth has been robust, with earnings rising by over 25% in the past year, outstripping the stock’s 21% return during the same period. The price-to-earnings-to-growth (PEG) ratio stands below 1, suggesting that the stock is reasonably valued given its earnings momentum. Promoter holdings remain substantial, signalling confidence from the company’s principal shareholders. Moreover, the stock has consistently outperformed the BSE500 index over the last three annual periods, underscoring its resilience and steady returns.